Vertex Pharmaceuticals Incorporated is a global biotechnology company focused on developing and commercializing medicines for serious diseases. Founded in 1989 and headquartered in Boston, Massachusetts, the company applies expertise in the science of human disease to discover therapies that address significant unmet medical needs.
Vertex is best known for its cystic fibrosis portfolio, which includes Kalydeco, Orkambi, Symdeko/Symkevi, and Trikafta/Kaftrio. These medicines target the underlying cause of cystic fibrosis for patients with specific mutations in the CFTR gene. The company also markets Casgevy, a gene-editing therapy developed in collaboration with CRISPR Therapeutics for sickle cell disease and transfusion-dependent beta thalassemia.
In addition to its cystic fibrosis and genetic-disease programs, Vertex develops treatments in areas including acute and chronic pain, kidney disease, and type 1 diabetes. Its non-opioid pain medicine, Journavx (suzetrigine), is designed to treat moderate to severe acute pain. Vertex serves patients and healthcare providers in the United States and international markets through its commercial operations and global research and development activities.
Reshma Kewalramani has served as Vertex’s president and chief executive officer since 2017. The company continues to invest in research aimed at developing medicines that address the underlying biology of disease rather than primarily managing symptoms.
AI Generated. May Contain Errors.
